Insight journal - Company

Valeant: M&A activity 2005-2013

Posted on 07 June 2013

Tags: , ,

Valeant has announced 30 M&A deals since 2005, with the lead deals being the acquisition of Medicis, Biovail.

Abstracted from: Partnering Deals and Alliances with Valeant Pharmaceuticals

Valeant is involved in M&A activity for growth similar to its peers in the list of top pharmaceutical companies. Valeant has frequently sought growth through strategic acquisition, for example when acquiring Medicis and Biovail.

Growth by acquisition can be considered to be one of Valeant’s core approaches to corporate development

The following figure shows the level of Valeant M&A deal announcements since 2005.

Figure 1: Valeant M&A deals 2005-2012

Valeant manda

Source: Current Agreements, 2013

Valeant has signed 30 M&A deals since 2005. Companies acquired include:

iNova Pharmaceuticals

Medicis

Obagi Medical Products

Orapharma

Probiotica

View the full list at Current Agreements (subscription required)

Valeant has been attracted to acquisition transactions whereby the company expands through the acquisition and assimilation of strategic target assets to realize business growth.

The following figure provides a summary of the top M&A deals by headline value.

Figure 2: Top Valeant M&A deals by headline value 2005-2013

Valeant top manda

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal. See: Partnering Deals and Alliances with Valeant Pharmaceuticals

Valeant M&A at Current Agreements                      

View all M&A deals for Valeant: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Deals and Alliances with Valeant Pharmaceuticals

More

Summary profile data for Valeant

Partnering interests for Valeant 

Partnering activity for Valeant 

 

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Valeant Pharmaceuticals

Report: Partnering Deals and Alliances with Big Pharma

 

Available resources for deal coverage for Valeant         

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Valeant company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif